Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Abstract 2606: Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B

Khalid A. Mohamedali, Lawrence H. Cheung, Mihai G. Iurascu, Louis R. DePalatis, Claire Thuning-Roberson, Michael G. Rosenblum

Cancer Res (2024) 84 (6_Supplement): 2606.

https://doi.org/10.1158/1538-7445.AM2024-2606

Published: 22 March 2024

View article titled, Abstract 2606: Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B

Journal Articles

Abstract 2603: Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Michael G. Rosenblum

Cancer Res (2024) 84 (6_Supplement): 2603.

https://doi.org/10.1158/1538-7445.AM2024-2603

Published: 22 March 2024

View article titled, Abstract 2603: Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B

Journal Articles

Abstract 5974: Targeting VEGFR on tumor cells and activated vasculature through delivery of granzyme B

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2024) 84 (6_Supplement): 5974.

https://doi.org/10.1158/1538-7445.AM2024-5974

Published: 22 March 2024

View article titled, Abstract 5974: Targeting VEGFR on tumor cells and activated vasculature through delivery of granzyme B

Journal Articles

Abstract 3901: Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Ganiraju C. Manyam, Jing Wang, John V. Heymach, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 3901.

https://doi.org/10.1158/1538-7445.AM2023-3901

Published: 04 April 2023

View article titled, Abstract 3901: Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B

Journal Articles

Abstract 6317: Targeting cell-surface CEA with a novel human fusion construct delivers the serine protease granzyme B to solid tumor cells

Khalid A. Mohamedali, Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6317.

https://doi.org/10.1158/1538-7445.AM2023-6317

Published: 04 April 2023

View article titled, Abstract 6317: Targeting cell-surface CEA with a novel human fusion construct delivers the serine protease granzyme B to solid tumor cells

Journal Articles

Abstract 6316: In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin

Khalid A. Mohamedali, Lawrence H. Cheung, Louis R. DePalatis, Claire Thuning-Roberson, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6316.

https://doi.org/10.1158/1538-7445.AM2023-6316

Published: 04 April 2023

View article titled, Abstract 6316: In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin

Journal Articles

Abstract 6315: Human granzyme B fusions targeting VEGFR on tumor cells and activated vasculature

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6315.

https://doi.org/10.1158/1538-7445.AM2023-6315

Published: 04 April 2023

View article titled, Abstract 6315: Human granzyme B fusions targeting VEGFR on tumor cells and activated vasculature

Journal Articles

Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Natalia Baran, Marina Konopleva, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6314.

https://doi.org/10.1158/1538-7445.AM2023-6314

Published: 04 April 2023

View article titled, Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Journal Articles

Abstract 6313: IND-enabling studies for GrB-Fc-IT4: in vivo efficacy, pharmacokinetics, schedule optimization and maximum tolerated dose

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Mihai Gagea, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6313.

https://doi.org/10.1158/1538-7445.AM2023-6313

Published: 04 April 2023

View article titled, Abstract 6313: IND-enabling studies for GrB-Fc-IT4: <em>in vivo</em> efficacy, pharmacokinetics, schedule optimization and maximum tolerated dose

Journal Articles

Abstract 337: Development of an immune-oncology agent containing granzyme B to target VEGFR+ ovarian cancer cells and activated tumor vasculature

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2022) 82 (12_Supplement): 337.

https://doi.org/10.1158/1538-7445.AM2022-337

Published: 15 June 2022

View article titled, Abstract 337: Development of an immune-oncology agent containing granzyme B to target VEGFR+ ovarian cancer cells and activated tumor vasculature

Journal Articles

Abstract 3439: An internalizing anti-CEA construct for targeted delivery of granzyme B results in significant antitumor activity in human lung carcinoma xenografts

Lawrence H. Cheung, Khalid A. Mohamedali, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2022) 82 (12_Supplement): 3439.

https://doi.org/10.1158/1538-7445.AM2022-3439

Published: 15 June 2022

View article titled, Abstract 3439: An internalizing anti-CEA construct for targeted delivery of granzyme B results in significant antitumor activity in human lung carcinoma xenografts

Journal Articles

Abstract 5216: Optimizing antitumor efficacy of granzyme B human fusion constructs targeting the Fn14 antigen in solid tumors. Pre IND pharmacokinetics, schedule, dose optimization and MTD studies

Ana Alvarez De Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Mihai Gagea, Michael G. Rosenblum

Cancer Res (2022) 82 (12_Supplement): 5216.

https://doi.org/10.1158/1538-7445.AM2022-5216

Published: 15 June 2022

View article titled, Abstract 5216: Optimizing antitumor efficacy of granzyme B human fusion constructs targeting the Fn14 antigen in solid tumors. Pre IND pharmacokinetics, schedule, dose optimization and MTD studies

Journal Articles

Abstract 5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics

Khalid A. Mohamedali, Lawrence H. Cheung, Ana A. Alvarez-Cienfuegos, Michael G. Rosenblum

Cancer Res (2020) 80 (16_Supplement): 5194.

https://doi.org/10.1158/1538-7445.AM2020-5194

Published: 15 August 2020

View article titled, Abstract 5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics

Journal Articles

Abstract 2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b

Khalid A. Mohamedali, Kok Su-yin, Lawrence H. Cheung, Naina Dhawan, Michael G. Rosenblum, Madhuri Wadehra

Cancer Res (2020) 80 (16_Supplement): 2891.

https://doi.org/10.1158/1538-7445.AM2020-2891

Published: 15 August 2020

View article titled, Abstract 2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b

Journal Articles

Abstract 5176: A novel, completely human fusion construct containing active Granzyme B efficiently kills Folate Receptor alpha positive tumor cells

Ana Alvarez de Cienfuegos, Laurence H. Cheung, Khalid A. Mohamedali, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2020) 80 (16_Supplement): 5176.

https://doi.org/10.1158/1538-7445.AM2020-5176

Published: 15 August 2020

View article titled, Abstract 5176: A novel, completely human fusion construct containing active Granzyme B efficiently kills Folate Receptor alpha positive tumor cells

Journal Articles

Abstract 2396: Development of a new generation of dimeric, highly cytotoxic fusion proteins containing active GrB and VEGF targeting tumor neovasculature: Incorporating IgG heavy chain Fc fragments improves cytotoxicity, stability and pharmacokinetics

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Michael G. Rosenblum

Cancer Res (2019) 79 (13_Supplement): 2396.

https://doi.org/10.1158/1538-7445.AM2019-2396

Published: 01 July 2019

View article titled, Abstract 2396: Development of a new generation of dimeric, highly cytotoxic fusion proteins containing active GrB and VEGF targeting tumor neovasculature: Incorporating IgG heavy chain Fc fragments improves cytotoxicity, stability and pharmacokinetics

Journal Articles

Abstract 4182: Impacting early events in metastatic spread: Targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Khalid A. Mohamedali, Lawrence H. Cheung, Michael G. Rosenblum

Cancer Res (2018) 78 (13_Supplement): 4182.

https://doi.org/10.1158/1538-7445.AM2018-4182

Published: 01 July 2018

View article titled, Abstract 4182: Impacting early events in metastatic spread: Targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Journal Articles

Abstract 2780: Engineering human fusion constructs for targeted delivery of granzyme B to CD33 and CEA antigens

Lawrence H. Cheung, Khalid A. Mohamedali, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2018) 78 (13_Supplement): 2780.

https://doi.org/10.1158/1538-7445.AM2018-2780

Published: 01 July 2018

View article titled, Abstract 2780: Engineering human fusion constructs for targeted delivery of granzyme B to CD33 and CEA antigens

Journal Articles

Abstract 2779: Molecular mechanistic and in vivo efficacy studies of Fn14-targeted fusion constructs containing human granzyme B

Ana Alvarez de Cienfuegos, Lawrence A. Cheung, Khalid A. Mohamedali, Landon J. Inge, Timothy Whitsett, Jeffrey A. Winkles, Louis DePalatis, Linda Paradiso, Michael G. Rosenblum

Cancer Res (2018) 78 (13_Supplement): 2779.

https://doi.org/10.1158/1538-7445.AM2018-2779

Published: 01 July 2018

View article titled, Abstract 2779: Molecular mechanistic and <em>in vivo</em> efficacy studies of Fn14-targeted fusion constructs containing human granzyme B

Journal Articles

Abstract 1628: Early events in metastatic spread: new approaches using targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Khalid A. Mohamedali, Lawrence H. Cheung, Michael G. Rosenblum

Cancer Res (2017) 77 (13_Supplement): 1628.

https://doi.org/10.1158/1538-7445.AM2017-1628

Published: 01 July 2017

View article titled, Abstract 1628: Early events in metastatic spread: new approaches using targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

NARROW

Abstract 2606: Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B

Abstract 2603: Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B

Abstract 5974: Targeting VEGFR on tumor cells and activated vasculature through delivery of granzyme B

Abstract 3901: Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B

Abstract 6317: Targeting cell-surface CEA with a novel human fusion construct delivers the serine protease granzyme B to solid tumor cells

Abstract 6316: In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin

Abstract 6315: Human granzyme B fusions targeting VEGFR on tumor cells and activated vasculature

Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Abstract 6313: IND-enabling studies for GrB-Fc-IT4: in vivo efficacy, pharmacokinetics, schedule optimization and maximum tolerated dose

Abstract 337: Development of an immune-oncology agent containing granzyme B to target VEGFR+ ovarian cancer cells and activated tumor vasculature

Abstract 3439: An internalizing anti-CEA construct for targeted delivery of granzyme B results in significant antitumor activity in human lung carcinoma xenografts

Abstract 5216: Optimizing antitumor efficacy of granzyme B human fusion constructs targeting the Fn14 antigen in solid tumors. Pre IND pharmacokinetics, schedule, dose optimization and MTD studies

Abstract 5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics

Abstract 2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b

Abstract 5176: A novel, completely human fusion construct containing active Granzyme B efficiently kills Folate Receptor alpha positive tumor cells

Abstract 2396: Development of a new generation of dimeric, highly cytotoxic fusion proteins containing active GrB and VEGF targeting tumor neovasculature: Incorporating IgG heavy chain Fc fragments improves cytotoxicity, stability and pharmacokinetics

Abstract 4182: Impacting early events in metastatic spread: Targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Abstract 2780: Engineering human fusion constructs for targeted delivery of granzyme B to CD33 and CEA antigens

Abstract 2779: Molecular mechanistic and in vivo efficacy studies of Fn14-targeted fusion constructs containing human granzyme B

Abstract 1628: Early events in metastatic spread: new approaches using targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only